Therapy News and Research

RSS

Skin cells for repairing cartilage injury

In this paper, Noriyuki Tsumaki and his team at the Osaka University Graduate School of Medicine, used fibroblasts isolated from adult mouse skin, and expressed proteins used to induce pluripotency along with a factor that promotes a chondrocyte fate.

11 Jan 2011

Researchers report gene therapy strategy that improves Beta Thalassemia in mice model

Researchers at Nationwide Children's Hospital report a gene therapy strategy that improves the condition of a mouse model of an inherited blood disorder, Beta Thalassemia.

11 Jan 2011

Pro-Pharmaceuticals to begin DAVANAT Phase III development program following FDA approval

Pro-Pharmaceuticals, the leading developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced that on December 17, 2010, Company representatives met with officials from the U.S. Food & Drug Administration to present its Phase III clinical development program for DAVANAT.

11 Jan 2011

Bristol-Myers Squibb, OPKO Health collaborate in relation to new diagnostic test technology

OPKO Health, Inc. today announced that it has entered into a collaboration agreement with Bristol-Myers Squibb Company relating to OPKO's new diagnostic test technology. OPKO's simple blood tests are being developed, based on its proprietary platform technology, to identify biomarkers for a wide variety of diseases including neurodegenerative disorders and various malignancies.

11 Jan 2011

Silicon microdevices may provide new way to screen metastatic breast cancer cells

Research by engineers and cancer biologists at Virginia Tech indicate that using specific silicon microdevices might provide a new way to screen breast cancer cells' ability to metastasize.

11 Jan 2011

NPS completes treatment phase in GATTEX Phase 3 registration study in short bowel syndrome

NPS Pharmaceuticals, Inc. a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today announced the completion of the 24-week treatment phase of the company's Phase 3 registration study of GATTEX® (teduglutide).

11 Jan 2011

American Medical Systems fourth quarter sales increase 0.7% to $147.0 million

In anticipation of presenting at the JP Morgan Healthcare Conference on January 11, 2011, American Medical Systems Holdings, Inc. reported today preliminary sales of $147.0 million for the fourth quarter of 2010, a 0.7 percent increase over sales of $146.0 million in the comparable quarter of 2009.

11 Jan 2011

Nationwide Children's Hospital receives $11.5 million NCI grant for Biospecimen banking

Nationwide Children's Hospital was awarded $11.5 million from the National Cancer Institute late last year to continue its role as one of two Biospecimen Core Resources for The Cancer Genome Atlas.

11 Jan 2011

Baylor Hamilton offers Arctic Front Cardiac CryoAblation Catheter system treatment for paroxysmal atrial fibrillation

Physicians at Baylor Jack and Jane Hamilton Heart and Vascular Hospital are the first in North Texas to offer the Arctic Front® Cardiac CryoAblation Catheter system, the first and only cryoballoon in the United States indicated to treat drug refractory recurrent symptomatic paroxysmal atrial fibrillation (PAF), a serious heart rhythm disorder that affects millions of Americans.

11 Jan 2011

Plasminogen may serve as new target to treat prion diseases

Scientists at the University of Kentucky have discovered that plasminogen, a protein used by the body to break up blood clots, speeds up the progress of prion diseases such as mad cow disease.

11 Jan 2011

Nutriceuticals may restore age-related vision loss

While age-related vision loss of catastrophic proportions is predicted in coming decades, rising from 17 million patients today to 55 million by the year 2050, it's possible this catastrophe could be averted and lost vision even restored using molecular medicine.

11 Jan 2011

Lineagen introduces FirstStep integrated genetic testing for early diagnostic evaluation of ASD, DD

Lineagen announces the launch of its FirstStep integrated genetic testing and counseling service to assist pediatricians and family physicians with the earlier, more accurate diagnostic evaluation of autism spectrum disorders and developmental delay.

11 Jan 2011

Study: Protein that plays a key role in some antioxidant therapies can promote atherosclerosis

UCLA researchers have found that a protein that plays an important role in some antioxidant therapies may not be as effective due to additional mechanisms that cause it to promote atherosclerosis, or clogging of the arteries.

11 Jan 2011

Enobia Pharma completes ENB-0040 Phase II study in juveniles with hypophosphatasia

Enobia Pharma, today announced that it has successfully completed a Phase II study of ENB-0040, a bone targeted enzyme replacement therapy being investigated in juveniles with hypophosphatasia, a serious, rare metabolic bone disorder.

10 Jan 2011

VCU Massey Cancer Center introduces safer, more effective form of radiation therapy

Virginia Commonwealth University Massey Cancer Center has introduced a safer and more effective form of radiation therapy to treat cancer. The Center now offers volumetric modulated arc therapy (VMAT) delivery using the Philips Pinnacle3 SmartArc software to provide radiation treatment for multiple tumor sites, including prostate, head and neck, brain, breast and lung. VCU Massey is the first cancer center in the Richmond area to offer this cutting-edge radiation technique.

10 Jan 2011

World's first drug eluting bioresorbable vascular scaffold receives CE Mark approval

Abbott announced today that it has received CE Mark approval for the world's first drug eluting bioresorbable vascular scaffold (BVS) for the treatment of coronary artery disease. Abbott's BVS device restores blood flow by opening a clogged vessel and providing support to the vessel until the device dissolves within approximately two years, leaving patients with a treated vessel free of a permanent metallic implant. Abbott's BVS device will be commercialized under the brand name ABSORB.

10 Jan 2011

Celator, Cephalon extend cancer research agreement

Celator Pharmaceuticals today announced that it has agreed with Cephalon, Inc. to extend an existing research agreement into the next phase of development. The research agreement provides for the utilization of Celator's proprietary technology in an ongoing drug development and life-cycle management program at Cephalon.

10 Jan 2011

Genetics Squared to change corporate name to Everist Genomics

Genetics Squared, a prognostics company focused on developing gene-based molecular assays for the prediction of cancer recurrence, today announced that it will change its corporate name to Everist Genomics and has appointed Prasad Sunkara, Ph.D. as its new President and Chief Executive Officer, effective immediately.

10 Jan 2011

Shionogi brings KAPVAY ADHD drug to the U.S market

Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced a true milestone as it marks the first commercial availability for the non-central nervous system stimulant medication KAPVAY™, an extended-release oral formulation of clonidine for Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents.

10 Jan 2011

Vicept reports positive data from V-101 Phase II clinical trial for Type I Rosacea

Vicept Therapeutics, Inc. announced positive study results from a Phase II clinical trial evaluating the dose-response relationship of four concentrations of V-101 cream, a topical cream for the treatment of Type I Rosacea (Erythematotelangiectatic Rosacea). The results demonstrated a statistically significantrebound" or tachyphylaxis was observed.

10 Jan 2011

Therapy News and Research

Skin cells for repairing cartilage injury

Researchers report gene therapy strategy that improves Beta Thalassemia in mice model

Pro-Pharmaceuticals to begin DAVANAT Phase III development program following FDA approval

Bristol-Myers Squibb, OPKO Health collaborate in relation to new diagnostic test technology

Silicon microdevices may provide new way to screen metastatic breast cancer cells

NPS completes treatment phase in GATTEX Phase 3 registration study in short bowel syndrome

American Medical Systems fourth quarter sales increase 0.7% to $147.0 million

Nationwide Children's Hospital receives $11.5 million NCI grant for Biospecimen banking

Baylor Hamilton offers Arctic Front Cardiac CryoAblation Catheter system treatment for paroxysmal atrial fibrillation

Plasminogen may serve as new target to treat prion diseases

Nutriceuticals may restore age-related vision loss

Lineagen introduces FirstStep integrated genetic testing for early diagnostic evaluation of ASD, DD

Study: Protein that plays a key role in some antioxidant therapies can promote atherosclerosis

Enobia Pharma completes ENB-0040 Phase II study in juveniles with hypophosphatasia

VCU Massey Cancer Center introduces safer, more effective form of radiation therapy

World's first drug eluting bioresorbable vascular scaffold receives CE Mark approval

Celator, Cephalon extend cancer research agreement

Genetics Squared to change corporate name to Everist Genomics

Shionogi brings KAPVAY ADHD drug to the U.S market

Vicept reports positive data from V-101 Phase II clinical trial for Type I Rosacea

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News